D
Damien Y. Duveau
Researcher at National Institutes of Health
Publications - 24
Citations - 1462
Damien Y. Duveau is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Gene & Cancer. The author has an hindex of 14, co-authored 22 publications receiving 1054 citations.
Papers
More filters
Journal ArticleDOI
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells
Lesley A. Mathews Griner,Rajarshi Guha,Paul Shinn,Ryan M. Young,Jonathan M. Keller,Dongbo Liu,Ian S. Goldlust,Adam Yasgar,Crystal McKnight,Matthew B. Boxer,Damien Y. Duveau,Jian-kang Jiang,Sam Michael,Tim Mierzwa,Wenwei Huang,Martin J. Walsh,Bryan T. Mott,Paresma R. Patel,Paresma R. Patel,William Leister,David J. Maloney,Christopher A. LeClair,Ganesha Rai,Ajit Jadhav,Brian D. Peyser,Christopher P. Austin,Scott E. Martin,Anton Simeonov,Marc Ferrer,Louis M. Staudt,Craig J. Thomas +30 more
TL;DR: A high-throughput screening platform capable of testing compounds in pairwise matrix blocks for the rapid and systematic identification of synergistic, additive, and antagonistic drug combinations for diffuse large B-cell lymphoma (DLBCL).
Journal ArticleDOI
Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma
Humsa S. Venkatesh,Lydia T. Tam,Pamelyn Woo,James Lennon,Surya Nagaraja,Shawn M. Gillespie,Jing Ni,Damien Y. Duveau,Patrick J. Morris,Jean J. Zhao,Craig J. Thomas,Michelle Monje +11 more
TL;DR: It is shown that HGG growth depends on microenvironmental NLGN3, identifying signalling cascades downstream of NL GN3 binding in glioma, and determining a therapeutically targetable mechanism of secretion are determined, which could prove transformative for HGG therapy.
Journal ArticleDOI
A Small Molecule That Inhibits OGT Activity in Cells
Rodrigo F. Ortiz-Meoz,Jiaoyang Jiang,Michael B. Lazarus,Marina Orman,John Janetzko,Chenguang Fan,Damien Y. Duveau,Zhi Wei Tan,Craig J. Thomas,Suzanne Walker +9 more
TL;DR: A small molecule OGT inhibitor, OSMI-1, developed from a high-throughput screening hit is cell-permeable and inhibits protein O-GlcNAcylation in several mammalian cell lines without qualitatively altering cell surface N- or O-linked glycans.
Journal ArticleDOI
Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
Grant L. Lin,Kelli M. Wilson,Michele Ceribelli,Benjamin Z. Stanton,Pamelyn Woo,Sara Kreimer,Elizabeth Y. Qin,Xiaohu Zhang,James Lennon,Surya Nagaraja,Patrick J. Morris,Michael Quezada,Shawn M. Gillespie,Damien Y. Duveau,Aleksandra M. Michalowski,Paul Shinn,Rajarshi Guha,Marc Ferrer,Carleen Klumpp-Thomas,Sam Michael,Crystal McKnight,Paras S. Minhas,Zina Itkin,Eric H. Raabe,Lu Chen,Reem A. Ghanem,Anna Geraghty,Lijun Ni,Katrin I. Andreasson,Nicholas A Vitanza,Katherine E. Warren,Craig J. Thomas,Michelle Monje +32 more
TL;DR: This study provides a comprehensive single-agent and combinatorial drug screen for DMG and identifies concomitant HDAC and proteasome inhibition as a promising therapeutic strategy that underscores underrecognized metabolic vulnerabilities in DMG.
Journal ArticleDOI
Structure-Based Evolution of Low Nanomolar O-GlcNAc Transferase Inhibitors
Sara E. S. Martin,Zhi-Wei Tan,Harri M. Itkonen,Damien Y. Duveau,Joao A. Paulo,John Janetzko,Paul L. Boutz,Lisa Törk,Frederick A. Moss,Craig J. Thomas,Steven P. Gygi,Michael B. Lazarus,Suzanne Walker +12 more
TL;DR: The structure-based evolution of OGT inhibitors culminating in compounds with low nanomolar inhibitory potency and on-target cellular activity are reported, providing insight into how to inhibit glycosyltransferases, a family of enzymes that has been notoriously refractory to inhibitor development.